Why Amedisys (AMED) Stock Is Gaining Today

NEW YORK (TheStreet) -- Amedisys (AMED) shares are shooting up 17.9% to $15.86 on Friday after the company previewed its second quarter earnings results.

The health care company projected a surprise profit of between 15 cents and 20 cents per share on revenue of $300 million to $305 million. Analyst had expected the company to break even for the quarter on revenue of $299.6 million.

The improved outlook rests on cost cutting measures the company has undertaken during the quarter.

Must ReadWarren Buffett's 25 Favorite Stocks

TheStreet Ratings team rates AMEDISYS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:

"We rate AMEDISYS INC (AMED) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share."

If you liked this article you might like

Here's What Blackstone Bought and Sold in the Fourth Quarter

Here's What Blackstone and KKR Are Buying

Republican Sweep Poised to Agitate ACA-Vulnerable Health Care Services Stocks

Blackstone, KKR Unveil Second-Quarter Stock Picks

Blackstone, KKR Stock Picks Show Distinctly Bullish Tone